Cite
HARVARD Citation
Basu, A. et al. (2017). Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert review of pharmacoeconomics & outcomes research. pp. 121-131. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Basu, A. et al. (2017). Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert review of pharmacoeconomics & outcomes research. pp. 121-131. [Online].